We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » KING-MYLAN MERGER IN DOUBT; KING TO RESTATE EARNINGS
KING-MYLAN MERGER IN DOUBT; KING TO RESTATE EARNINGS
January 11, 2005
Brand drugmaker King Pharmaceuticals announced last month that it intends to restate its earnings for 2002, 2003 and the first six months of 2004 — an action that could prompt Mylan Laboratories to terminate its pending merger with King without having to pay an $85 million penalty fee.